Impact of the Inclusion of an Aminoglycoside to the Initial Empirical Antibiotic Therapy for Gram-Negative Bloodstream Infections in Hematological Neutropenic Patients: a Propensity-Matched Cohort Study (AMINOLACTAM Study)
Adaia Albasanz‐Puig, Carlota Gudiol, Pedro Puerta‐Alcalde, Çağlayan Merve Ayaz, Marina Machado, Fabián Herrera, Pilar Martín‐Dávila, Júlia Laporte-Amargós, Celia Cardozo, Murat Akova, A. Álvarez-Uría, Diego Torres, Jesús Fortün, Carolina García‐Vidal, Patricia Muñóz, Alba Bergas, Helena Pomares, Santiago Mercadal, Xavier Durà-Miralles, Esther García-Lerma, Natàlia Pallarés, Jordi Carratalà
Abstract
To test the hypothesis that the addition of an aminoglycoside to a β-lactam antibiotic could provide better outcomes than β-lactam monotherapy for the initial empirical treatment of hematological neutropenic patients with subsequently documented Gram-negative bacillus (GNB) bloodstream infection (BSI), a multinational, retrospective, cohort study of GNB BSI episodes in hematological neutropenic patients in six centers (2010 to 2017) was conducted. Combination therapy (β-lactam plus aminoglycoside) was compared to β-lactam monotherapy.